23Andme Holding Co Stock Price, News & Analysis

23andMe (Nasdaq: ME) has initiated voluntary Chapter 11 proceedings to facilitate a court-supervised sale process, aiming to maximize business value. The company secured $35 million in DIP financing from JMB Capital Partners to support ongoing operations.

Key developments include:

• CEO Anne Wojcicki's resignation, with CFO Joe Selsavage appointed as Interim CEO
• Matt Kvarda appointed as Chief Restructuring Officer
• Plans to reject real estate leases in Sunnyvale and San Francisco
• Intent to resolve legal liabilities from October 2023 cyber incident

The company will conduct a 45-day bidding process for qualified buyers, potentially leading to an auction. Customer data management remains unchanged, and any potential buyer must comply with applicable data privacy laws. The Special Committee rejected Wojcicki's final non-binding acquisition proposal made on March 10, 2025.

23andMe (ME) has launched a new genetic report and optional blood test for homocysteine levels, exclusively available to 23andMe+ Premium members. The report analyzes two common genetic variants in the MTHFR gene (C677T and A1298C) that may indicate a predisposition to slightly elevated homocysteine levels.

The highly requested feature allows users to understand their genetic likelihood of developing elevated homocysteine levels, an amino acid that requires vitamins B6, B12, and folate for proper processing. Elevated levels may increase risks of cognitive decline and stroke. The company is also offering an optional laboratory test for customers to directly measure their homocysteine levels.

This launch represents a step toward personalized preventive medicine, combining genetic insights with traditional blood testing. The report acknowledges its limitations, noting that it doesn't account for all possible genetic variants or non-genetic factors affecting homocysteine levels.

The Special Committee of 23andMe's Board of Directors (Nasdaq: ME) has unanimously rejected a non-binding acquisition proposal from CEO Anne Wojcicki. The proposal aimed to acquire all outstanding shares not owned by Wojcicki and her affiliates for $0.41 per share.

This new offer represents an 84% decrease from the previous joint non-binding proposal of $2.53 per share submitted on February 20, 2025. The proposal was disclosed in an amended Schedule 13D filing with the SEC.

Moelis & Company and Goodwin Procter LLP are serving as financial and legal advisors respectively to the Special Committee, which has stated it will not provide further comments until required.

23andMe (Nasdaq: ME) has launched a new polygenic risk score (PRS) report for osteoporosis, exclusively available to 23andMe+ Premium members. The report analyzes thousands of genetic variants to assess an individual's likelihood of developing osteoporosis, a condition affecting bone density that impacts approximately 12.3 million Americans, with an additional 40+ million having osteopenia.

The PRS report utilizes 23andMe's proprietary research database to create a statistical model considering genetic markers, ancestry, and birth sex. According to published data, genetics accounts for 60-80% of bone density variability. The report also provides actionable lifestyle recommendations to help reduce risk factors.

Osteoporosis, often called a 'silent' disease, results in approximately 2 million new fractures annually in the U.S., exceeding the combined number of new heart attacks, breast cancer, and prostate cancer cases. Despite its significant health impact, about 80% of individuals with osteoporosis-related fractures remain untested and untreated.

23andMe (Nasdaq: ME) announced that its Special Committee of the Board of Directors has initiated a process to explore strategic alternatives. The potential options under consideration include a possible sale of the company, business combination, sale of all or part of company assets, licensing of assets, restructuring, or other strategic actions.

The Special Committee, composed of independent directors, has engaged Moelis & Company as financial advisor and Goodwin Procter LLP as legal advisor. The company emphasized that there is no guarantee that this exploration will result in any agreements or transactions. Updates will only be provided when definitive agreements are reached or when required by law.

23andMe (ME) reported Q3 FY25 financial results showing significant challenges. Total revenue was $60.3 million, including $19.3 million in non-recurring research services revenue. Consumer Services Revenue declined 8% to $39.6 million compared to the prior year.

The company implemented a 40% reduction in force with expected annual savings of $35+ million and discontinued its Therapeutics business. Cash position decreased to $79.4 million as of December 31, 2024, from $216.5 million in March 2024.

Management expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional liquidity. The previously announced $30 million cyber incident settlement wasn't unconditionally approved by the court. Net loss for Q3 was $26.8 million, improved from $259.7 million in the prior year quarter.

23andMe (Nasdaq: ME) has launched Discover23, a new research platform enabling authorized collaborators to securely access the company's vast genetic research data through a Trusted Research Environment (TRE) developed by Lifebit. The platform provides analysis-ready genome-wide association studies (GWAS) on over 1,000 disease and condition cohorts, leveraging 4.7B phenotypic data points.

The platform evaluates associations of 172 million genetic variants using data from consenting research participants, representing 84% of the company's 15 million customers. Discover23 aims to help identify novel disease biology, discover potential drug targets, and enhance clinical trial success rates. The platform ensures participant privacy by stripping personal identifiers and providing isolated workspaces for authorized researchers.

23andMe Holding Co. (Nasdaq: ME) and Mirador Therapeutics announced a strategic research collaboration focused on immunology and inflammation-related diseases. Mirador will utilize 23andMe's genetic and phenotypic database, the world's largest crowdsourced platform for genetic research, alongside their proprietary Mirador360™ development engine to advance target validation and precision medicine. The collaboration combines Mirador's extensive repository of immune-mediated disease data, including over two million human molecular profiles, with 23andMe's database, which has previously contributed to multiple drug discovery programs and two clinical stage assets in immuno-oncology.

23andMe reported Q2 FY25 financial results with total revenue of $44 million, down 12% from $50 million in the prior year. The company improved its GAAP Net Loss by 21% to $59 million and Adjusted EBITDA loss by 26% to $33 million. Operating expenses decreased 17% to $84 million. Membership services revenue grew to represent 21% of total revenue, up from 9% last year. The company ended the quarter with $127 million in cash and no debt, down from $216 million in March 2024. 23andMe launched new services including a GLP-1 weight loss telehealth membership and an AI chatbot called DaNA.